Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
cancer
New findings cast light on lymphatic system, key player in human health
OMRF researchers have broken new ground in understanding how the lymphatic system works.
Putnam City Schools donate $100,000 to cancer research at OMRF
Over the past 43 years, Putnam City students, teachers and families have raised more than $3.6 million to combat cancer.
Staying alive: Can an experimental OMRF drug stop Mike Schuster’s brain cancer?
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.
Federal grant brings $13.1 million to OMRF labs
The award is part of the Centers of Biomedical Research Excellence (COBRE) program.
OMRF receives $2.1 million to study cell division
OMRF scientist Gary Gorbsky, Ph.D., will use the funds to pursue general research projects related to cell division.
